Supporting early-stage innovations
We know that too many great ideas arising from research can stall at the earliest stages of translation, which can delay the development of much needed innovations ever getting to kidney patients. We're supporting start-ups to change this.
How we can support
A big challenge for start-up companies is attracting the early-stage capital funding to support the progression of a promising innovation, or to grow your company. Our Development Advisory Board (DAB) assesses cutting-edge ideas, provides advice, guidance and access to experts. Subject to due diligence and assessment, the DAB offers pre-seed and seed capital investment to give start-ups the best chance of success which enables companies to secure additional investment.
You don't need to be a Kidney Research UK-funded researcher to secure early seed capital investment from us. We’re interested in all ideas that could benefit kidney patients including:
- New therapies and treatments
- Better preventative measures
- Early and improved diagnostics
- Medical devices
- Artificial intelligence and data driven solutions
We invest in early-stage startup propositions and companies to bridge the gap between innovative ideas, treatments, diagnostics and medical devices so that one day we will end kidney disease.
If you have a question on how we might be able to support you, or for an informal confidential chat, drop us an email and a member of the team will be in touch.